Gradient Investments LLC Sells 43,675 Shares of Medtronic PLC $MDT

Gradient Investments LLC lessened its holdings in shares of Medtronic PLC (NYSE:MDT) by 8.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 452,838 shares of the medical technology company’s stock after selling 43,675 shares during the quarter. Gradient Investments LLC’s holdings in Medtronic were worth $39,075,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of Medtronic by 0.7% in the second quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock valued at $8,919,846,000 after acquiring an additional 838,220 shares during the period. State Street Corp grew its position in Medtronic by 2.7% during the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after purchasing an additional 1,658,301 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Medtronic by 5.4% during the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after buying an additional 1,343,220 shares during the period. First Eagle Investment Management LLC grew its holdings in shares of Medtronic by 37.2% during the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after buying an additional 3,739,288 shares during the last quarter. Finally, WCM Investment Management LLC acquired a new position in Medtronic in the 1st quarter valued at about $965,922,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Trading Up 2.7%

Shares of NYSE:MDT traded up $2.29 during midday trading on Thursday, reaching $87.80. The company’s stock had a trading volume of 48,592,137 shares, compared to its average volume of 10,245,308. The firm has a market cap of $112.31 billion, a price-to-earnings ratio of 21.71, a price-to-earnings-growth ratio of 1.98 and a beta of 0.55. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The business has a 50 day moving average price of $90.18 and a 200 day moving average price of $84.75.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The business had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same quarter in the previous year, the business earned $1.26 EPS. The company’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Research analysts forecast that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president directly owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.27% of the stock is owned by company insiders.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Barclays upgraded MDT to Hold. The move from a less favorable rating removes some analyst pressure on the stock and may support investor sentiment, though a Hold is not an outright bullish recommendation. Medtronic Stock Rating Raised to Hold at Barclays
• Positive Sentiment: Medtronic appointed Felicia Kurz as vice president and general manager of Cardiac Ablation Solutions. The leadership change comes as the company sees strong demand for electrophysiology therapies, particularly its pulsed-field ablation devices. Continued momentum in this business could strengthen Medtronic’s growth outlook. Medtronic names Felicia Kurz as cardiac ablation VP, GM
• Neutral Sentiment: Medtronic announced a final 4.5939 exchange ratio for its MiniMed split-off. The company plans to exchange up to approximately 225.4 million MiniMed Group (NASDAQ: MMED) shares for Medtronic ordinary shares, with the potential to exchange its remaining interest if the offer is oversubscribed. The transaction provides greater clarity on the separation but may also reduce MDT’s share count and ownership of MiniMed. Medtronic Announces Final Exchange Ratio
• Neutral Sentiment: Analyst coverage continues to emphasize MDT’s dividend appeal, with the stock included among healthcare companies offering relatively high yields. That may attract income-focused investors, but the commentary does not introduce a new earnings catalyst. Healthcare stocks with high dividend yields
• Neutral Sentiment: Medtronic’s FY2026 impact report said the company served more than 82 million patients worldwide, reinforcing its scale and healthcare reach but offering limited direct implications for near-term financial results. Medtronic FY2026 Impact Report

Wall Street Analyst Weigh In

Several analysts have recently commented on MDT shares. Mizuho set a $115.00 target price on shares of Medtronic in a research note on Wednesday, September 2nd. Bank of America increased their price target on shares of Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Weiss Ratings upgraded shares of Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, September 4th. Evercore set a $105.00 target price on Medtronic in a research report on Monday, July 6th. Finally, Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Eighteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.92.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.